Shanghai No.1 Pharmacy Co., Ltd. Logo

Shanghai No.1 Pharmacy Co., Ltd.

600833.SS

(2.0)
Stock Price

10,70 CNY

6.94% ROA

12.81% ROE

20.47x PER

Market Cap.

2.592.259.320,00 CNY

13.28% DER

1.68% Yield

5.72% NPM

Shanghai No.1 Pharmacy Co., Ltd. Stock Analysis

Shanghai No.1 Pharmacy Co., Ltd. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Shanghai No.1 Pharmacy Co., Ltd. Fundamental Stock Analysis
# Analysis Rating
1 Dividend

The company's consistent dividend payouts over the past five years exemplify its strong commitment to providing shareholders with reliable returns, making it an attractive investment option.

2 DER

The stock has a minimal amount of debt (13%) relative to its ownership, showcasing a strong financial position and lower risk for investors.

3 Buffet Intrinsic Value

The company's stock presents an enticing opportunity as it appears undervalued (253) by Warren Buffett's formula, indicating that its intrinsic value exceeds the market price.

4 ROE

ROE in an average range (12.81%) suggests satisfactory profitability and decent utilization of shareholders' equity.

5 ROA

The stock's ROA (6.94%) indicates that it's doing well in making money from the things it owns. This makes it a good option to invest and make consistent profits.

6 PBV

The stock's PBV ratio (2.63x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

7 Graham Number

The Graham number calculation reveals that this company's stock price is potentially inflated, implying that it may not be a desirable investment option.

8 Dividend Growth

The company's dividend growth has been flat for the past three years, raising concerns for potential investors seeking reliable returns.

9 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

10 Net Profit Growth

This company's net profit has remained flat over the past five years, suggesting a lack of growth and making it a less attractive investment opportunity.

11 Assets Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

Shanghai No.1 Pharmacy Co., Ltd. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Shanghai No.1 Pharmacy Co., Ltd. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Shanghai No.1 Pharmacy Co., Ltd. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Shanghai No.1 Pharmacy Co., Ltd. Revenue
Year Revenue Growth
1992 36.533.500
1993 56.284.300 35.09%
1994 122.530.240 54.06%
1995 207.374.550 40.91%
1996 276.341.607 24.96%
1997 290.165.202 4.76%
1998 -51.851.806 659.6%
1999 -9.220.915 -462.33%
2000 4.190.595 320.04%
2001 263.233.128 98.41%
2002 476.518.261 44.76%
2003 506.962.293 6.01%
2004 545.502.668 7.07%
2005 601.617.263 9.33%
2006 602.934.141 0.22%
2007 909.996.776 33.74%
2008 964.530.170 5.65%
2009 1.036.970.327 6.99%
2010 1.147.475.726 9.63%
2011 1.268.327.122 9.53%
2012 1.357.670.359 6.58%
2013 1.348.394.808 -0.69%
2014 1.414.745.420 4.69%
2015 1.490.959.755 5.11%
2016 1.519.029.397 1.85%
2017 1.556.146.205 2.39%
2018 1.176.665.762 -32.25%
2019 1.243.169.488 5.35%
2020 1.586.903.725 21.66%
2021 1.398.284.999 -13.49%
2022 2.655.908.524 47.35%
2023 1.750.254.848 -51.74%
2023 1.811.157.603 3.36%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Shanghai No.1 Pharmacy Co., Ltd. Research and Development Expenses
Year Research and Development Expenses Growth
1992 0
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Shanghai No.1 Pharmacy Co., Ltd. General and Administrative Expenses
Year General and Administrative Expenses Growth
1992 0
1993 0 0%
1994 0 0%
1995 17.807.823 100%
1996 16.452.871 -8.24%
1997 13.582.625 -21.13%
1998 19.968.737 31.98%
1999 29.653.651 32.66%
2000 15.980.489 -85.56%
2001 16.843.737 5.13%
2002 44.237.929 61.92%
2003 52.334.601 15.47%
2004 55.434.551 5.59%
2005 57.494.869 3.58%
2006 47.367.463 -21.38%
2007 62.740.500 24.5%
2008 64.511.953 2.75%
2009 63.935.208 -0.9%
2010 10.116.721 -531.98%
2011 10.421.016 2.92%
2012 12.816.416 18.69%
2013 11.691.093 -9.63%
2014 11.781.920 0.77%
2015 13.425.583 12.24%
2016 10.661.034 -25.93%
2017 10.292.983 -3.58%
2018 12.737.151 19.19%
2019 9.986.352 -27.55%
2020 13.000.683 23.19%
2021 9.097.568 -42.9%
2022 16.388.536 44.49%
2023 188.489.826 91.31%
2023 19.855.344 -849.32%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Shanghai No.1 Pharmacy Co., Ltd. EBITDA
Year EBITDA Growth
1992 -915.000
1993 -2.529.000 63.82%
1994 122.530.240 102.06%
1995 14.957.938 -719.17%
1996 64.696.788 76.88%
1997 64.811.805 0.18%
1998 -32.746.963 297.92%
1999 -26.607.679 -23.07%
2000 -51.366.491 48.2%
2001 35.219.342 245.85%
2002 28.668.265 -22.85%
2003 26.351.215 -8.79%
2004 32.083.719 17.87%
2005 33.018.267 2.83%
2006 32.342.474 -2.09%
2007 43.988.642 26.48%
2008 39.264.619 -12.03%
2009 64.728.647 39.34%
2010 51.981.221 -24.52%
2011 62.113.835 16.31%
2012 62.165.093 0.08%
2013 49.098.352 -26.61%
2014 57.877.457 15.17%
2015 49.661.360 -16.54%
2016 51.624.026 3.8%
2017 59.068.292 12.6%
2018 -14.193.835 516.15%
2019 82.074.972 117.29%
2020 106.161.183 22.69%
2021 114.286.937 7.11%
2022 296.483.858 61.45%
2023 29.013.690 -921.88%
2023 68.422.430 57.6%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Shanghai No.1 Pharmacy Co., Ltd. Gross Profit
Year Gross Profit Growth
1992 4.002.500
1993 9.156.300 56.29%
1994 122.530.240 92.53%
1995 38.545.281 -217.89%
1996 96.046.819 59.87%
1997 96.406.161 0.37%
1998 -26.505.261 463.72%
1999 -9.962.826 -166.04%
2000 -7.126.969 -39.79%
2001 56.893.129 112.53%
2002 109.558.458 48.07%
2003 117.049.792 6.4%
2004 119.174.481 1.78%
2005 119.303.757 0.11%
2006 106.038.252 -12.51%
2007 177.504.909 40.26%
2008 173.677.714 -2.2%
2009 184.612.328 5.92%
2010 200.783.293 8.05%
2011 217.500.022 7.69%
2012 234.439.410 7.23%
2013 219.991.975 -6.57%
2014 224.679.601 2.09%
2015 228.876.889 1.83%
2016 238.255.764 3.94%
2017 246.781.776 3.45%
2018 227.924.388 -8.27%
2019 248.810.096 8.39%
2020 282.244.813 11.85%
2021 248.010.619 -13.8%
2022 545.134.763 54.5%
2023 328.957.668 -65.72%
2023 290.042.102 -13.42%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Shanghai No.1 Pharmacy Co., Ltd. Net Profit
Year Net Profit Growth
1992 2.624.400
1993 13.466.400 80.51%
1994 24.780.820 45.66%
1995 18.833.711 -31.58%
1996 20.431.578 7.82%
1997 31.105.318 34.31%
1998 -140.280.227 122.17%
1999 -185.903.032 24.54%
2000 -136.539.890 -36.15%
2001 24.234.052 663.42%
2002 12.689.903 -90.97%
2003 12.912.258 1.72%
2004 13.133.154 1.68%
2005 14.205.413 7.55%
2006 12.969.535 -9.53%
2007 20.061.413 35.35%
2008 20.014.910 -0.23%
2009 40.003.637 49.97%
2010 30.324.417 -31.92%
2011 36.748.650 17.48%
2012 36.434.338 -0.86%
2013 34.266.800 -6.33%
2014 37.024.839 7.45%
2015 41.168.494 10.07%
2016 46.034.162 10.57%
2017 43.476.771 -5.88%
2018 47.186.332 7.86%
2019 53.089.382 11.12%
2020 68.540.922 22.54%
2021 49.419.058 -38.69%
2022 143.556.293 65.58%
2023 46.684.726 -207.5%
2023 89.275.234 47.71%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Shanghai No.1 Pharmacy Co., Ltd. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1992 0
1993 0 0%
1994 0 0%
1995 0 0%
1996 0 0%
1997 0 0%
1998 -1 0%
1999 -1 0%
2000 -1 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 1 0%
2023 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Shanghai No.1 Pharmacy Co., Ltd. Free Cashflow
Year Free Cashflow Growth
1998 -132.878.912
1999 -2.778.020 -4683.22%
2000 1.922.281 244.52%
2001 51.534.799 96.27%
2002 1.784.049 -2788.64%
2003 7.473.877 76.13%
2004 -5.792.956 229.02%
2005 10.796.043 153.66%
2006 67.607.811 84.03%
2007 33.144.441 -103.98%
2008 16.658.423 -98.97%
2009 21.995.757 24.27%
2010 29.620.480 25.74%
2011 15.341.245 -93.08%
2012 1.847.153 -730.54%
2013 -808.205 328.55%
2014 15.165.406 105.33%
2015 43.095.085 64.81%
2016 33.759.343 -27.65%
2017 106.489.692 68.3%
2018 33.667.906 -216.29%
2019 94.615.543 64.42%
2020 72.008.900 -31.39%
2021 23.919.652 -201.04%
2022 120.940.416 80.22%
2023 19.237.652 -528.67%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Shanghai No.1 Pharmacy Co., Ltd. Operating Cashflow
Year Operating Cashflow Growth
1998 -132.680.332
1999 -2.591.162 -5020.5%
2000 2.008.681 229%
2001 56.493.085 96.44%
2002 25.086.343 -125.19%
2003 26.295.447 4.6%
2004 2.925.466 -798.85%
2005 14.215.356 79.42%
2006 82.998.243 82.87%
2007 41.350.172 -100.72%
2008 20.715.405 -99.61%
2009 27.061.264 23.45%
2010 39.915.989 32.2%
2011 24.666.245 -61.82%
2012 56.248.128 56.15%
2013 6.519.981 -762.7%
2014 19.198.828 66.04%
2015 48.821.434 60.68%
2016 36.371.168 -34.23%
2017 120.074.113 69.71%
2018 42.793.436 -180.59%
2019 104.601.581 59.09%
2020 84.241.401 -24.17%
2021 36.559.507 -130.42%
2022 132.310.966 72.37%
2023 23.482.790 -463.44%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Shanghai No.1 Pharmacy Co., Ltd. Capital Expenditure
Year Capital Expenditure Growth
1998 198.580
1999 186.858 -6.27%
2000 86.400 -116.27%
2001 4.958.286 98.26%
2002 23.302.294 78.72%
2003 18.821.570 -23.81%
2004 8.718.422 -115.88%
2005 3.419.313 -154.98%
2006 15.390.432 77.78%
2007 8.205.731 -87.56%
2008 4.056.982 -102.26%
2009 5.065.507 19.91%
2010 10.295.509 50.8%
2011 9.325.000 -10.41%
2012 54.400.976 82.86%
2013 7.328.186 -642.35%
2014 4.033.422 -81.69%
2015 5.726.348 29.56%
2016 2.611.825 -119.25%
2017 13.584.421 80.77%
2018 9.125.530 -48.86%
2019 9.986.038 8.62%
2020 12.232.501 18.36%
2021 12.639.854 3.22%
2022 11.370.550 -11.16%
2023 4.245.138 -167.85%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Shanghai No.1 Pharmacy Co., Ltd. Equity
Year Equity Growth
1994 186.741.730
1995 182.278.025 -2.45%
1996 200.845.038 9.24%
1997 340.494.690 41.01%
1998 99.474.314 -242.29%
1999 -278.788.241 135.68%
2000 -400.760.732 30.44%
2001 165.524.210 342.12%
2002 176.308.151 6.12%
2003 189.220.409 6.82%
2004 202.353.564 6.49%
2005 232.679.278 13.03%
2006 244.892.435 4.99%
2007 392.769.859 37.65%
2008 313.535.760 -25.27%
2009 402.254.025 22.06%
2010 428.872.901 6.21%
2011 422.403.497 -1.53%
2012 492.834.840 14.29%
2013 529.129.476 6.86%
2014 643.963.404 17.83%
2015 776.083.618 17.02%
2016 728.988.794 -6.46%
2017 707.057.560 -3.1%
2018 669.568.047 -5.6%
2019 732.337.046 8.57%
2020 749.316.719 2.27%
2021 777.923.574 3.68%
2022 958.678.079 18.85%
2023 1.007.057.829 4.8%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Shanghai No.1 Pharmacy Co., Ltd. Assets
Year Assets Growth
1994 723.828.740
1995 1.217.218.435 40.53%
1996 1.384.583.884 12.09%
1997 1.175.606.442 -17.78%
1998 986.828.121 -19.13%
1999 745.712.202 -32.33%
2000 479.138.776 -55.64%
2001 482.760.968 0.75%
2002 478.386.082 -0.91%
2003 485.077.865 1.38%
2004 429.016.387 -13.07%
2005 343.664.168 -24.84%
2006 481.149.779 28.57%
2007 696.569.488 30.93%
2008 589.109.389 -18.24%
2009 721.570.618 18.36%
2010 788.178.974 8.45%
2011 794.206.116 0.76%
2012 892.267.793 10.99%
2013 916.162.638 2.61%
2014 1.080.979.886 15.25%
2015 1.230.134.682 12.13%
2016 1.185.287.124 -3.78%
2017 1.135.968.182 -4.34%
2018 1.079.466.352 -5.23%
2019 1.216.551.641 11.27%
2020 1.396.255.792 12.87%
2021 1.334.462.955 -4.63%
2022 2.039.102.174 34.56%
2023 1.863.599.619 -9.42%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Shanghai No.1 Pharmacy Co., Ltd. Liabilities
Year Liabilities Growth
1994 537.087.010
1995 929.627.388 42.23%
1996 1.079.258.157 13.86%
1997 830.273.128 -29.99%
1998 886.853.807 6.38%
1999 1.024.000.443 13.39%
2000 879.399.509 -16.44%
2001 317.236.759 -177.21%
2002 302.077.931 -5.02%
2003 295.589.834 -2.19%
2004 226.394.950 -30.56%
2005 110.984.890 -103.99%
2006 235.381.704 52.85%
2007 303.027.002 22.32%
2008 274.953.077 -10.21%
2009 319.316.593 13.89%
2010 352.298.757 9.36%
2011 364.795.304 3.43%
2012 392.425.637 7.04%
2013 380.025.846 -3.26%
2014 430.009.166 11.62%
2015 447.043.748 3.81%
2016 449.291.014 0.5%
2017 421.903.306 -6.49%
2018 409.898.304 -2.93%
2019 484.214.595 15.35%
2020 646.939.073 25.15%
2021 556.539.381 -16.24%
2022 1.080.424.095 48.49%
2023 856.541.790 -26.14%

Shanghai No.1 Pharmacy Co., Ltd. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
9.93
Net Income per Share
0.57
Price to Earning Ratio
20.47x
Price To Sales Ratio
1.17x
POCF Ratio
11.09
PFCF Ratio
11.83
Price to Book Ratio
2.59
EV to Sales
1.15
EV Over EBITDA
12.26
EV to Operating CashFlow
10.93
EV to FreeCashFlow
11.66
Earnings Yield
0.05
FreeCashFlow Yield
0.08
Market Cap
2,59 Bil.
Enterprise Value
2,55 Bil.
Graham Number
7.57
Graham NetNet
-0.15

Income Statement Metrics

Net Income per Share
0.57
Income Quality
2.37
ROE
0.13
Return On Assets
0.07
Return On Capital Employed
0.12
Net Income per EBT
0.76
EBT Per Ebit
1.19
Ebit per Revenue
0.06
Effective Tax Rate
0.24

Margins

Sales, General, & Administrative to Revenue
0.01
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.21
Operating Profit Margin
0.06
Pretax Profit Margin
0.08
Net Profit Margin
0.06

Dividends

Dividend Yield
0.02
Dividend Yield %
1.68
Payout Ratio
0.41
Dividend Per Share
0.2

Operating Metrics

Operating Cashflow per Share
1.05
Free CashFlow per Share
0.98
Capex to Operating CashFlow
-0.06
Capex to Revenue
-0.01
Capex to Depreciation
0
Return on Invested Capital
0.09
Return on Tangible Assets
0.07
Days Sales Outstanding
44.96
Days Payables Outstanding
109.49
Days of Inventory on Hand
60.46
Receivables Turnover
8.12
Payables Turnover
3.33
Inventory Turnover
6.04
Capex per Share
-0.07

Balance Sheet

Cash per Share
2,13
Book Value per Share
4,49
Tangible Book Value per Share
4.33
Shareholders Equity per Share
4.49
Interest Debt per Share
0.64
Debt to Equity
0.13
Debt to Assets
0.07
Net Debt to EBITDA
-0.18
Current Ratio
1.59
Tangible Asset Value
0,97 Bil.
Net Current Asset Value
0,25 Bil.
Invested Capital
0.13
Working Capital
0,41 Bil.
Intangibles to Total Assets
0.02
Average Receivables
0,27 Bil.
Average Payables
0,50 Bil.
Average Inventory
288887006.42
Debt to Market Cap
0.05

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Shanghai No.1 Pharmacy Co., Ltd. Dividends
Year Dividends Growth
1994 0
1995 0 0%
1996 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Shanghai No.1 Pharmacy Co., Ltd. Profile

About Shanghai No.1 Pharmacy Co., Ltd.

Shanghai No.1 Pharmacy Co., Ltd. engages in the retail and wholesale of pharmaceutical products. The company offers products in the categories of Chinese and Western medicines, nutrition and health products, medical equipment, Chinese herbal medicines, etc. In addition, it provides consulting and guidance on safe medication, rational medication, and chronic disease medication. Shanghai No. 1 Pharmacy Co., Ltd. is based in Shanghai, China.

CEO
Mr. Jun Yao
Employee
877
Address
681 Xiaomuqiao Road
Shanghai, 200032

Shanghai No.1 Pharmacy Co., Ltd. Executives & BODs

Shanghai No.1 Pharmacy Co., Ltd. Executives & BODs
# Name Age
1 Mr. Jun Yao
General Manager
70
2 Liuzhong Yue
Deputy Gen. Mang.
70
3 Mr. Feng Lin
Deputy Gen. Mang.
70
4 Ms. Yi Zhang
Deputy Gen. Mang.
70
5 Mr. Xian Cheng Wang
Deputy Gen. Mang.
70
6 Mr. Zheng Sun
Financial Director
70

Shanghai No.1 Pharmacy Co., Ltd. Competitors